Research and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., 3333-26, Aza-Asayama, Kamitezuna Takahagi-shi, Ibaraki, 318-0004, Japan.
Research and Development Division, Kyokuto Pharmaceutical Industrial Co., Ltd., 3333-26, Aza-Asayama, Kamitezuna Takahagi-shi, Ibaraki, 318-0004, Japan.
Protein Expr Purif. 2024 Feb;214:106374. doi: 10.1016/j.pep.2023.106374. Epub 2023 Oct 2.
We present an efficient method for expression and purification of recombinant human procalcitonin (hPCT) in E. coli T7 express LysY/Iq cells, ensuring precise N- and C-terminal amino acid sequences. Our method involves fusing codon-optimized cDNA with two distinct tag sequences: eXact tag and chitin binding domain (CBD) tag. To purify the protein, we employ a two-step affinity chromatography process. Firstly, we utilize the N-terminal Profinity eXact tag and purify the protein through Profinity eXact-affinity column chromatography using a resin on which a mutant subtilisin protease was immobilized. The eXact tag was removed by adding NaF to activate the enzyme. Subsequently, the digested sample containing C-terminal CBD tag is directly loaded for the second step of chitin affinity chromatography. Elution is achieved through dithiothreitol (DTT)-catalyzed self-cleavage of the intein sequence from the fusion protein. As a result, the target protein is selectively recovered in the flow-through, completely tag-free, with a purity exceeding 95%. To ensure high purity and eliminate potential contaminants, we effectively remove E. coli host DNA and endotoxins through a combination of streptomycin sulfate, Triton X-114, and ammonium sulfate treatment. The exceptional level of purity obtained eliminates the need for further purification steps in most applications. This highly purified hPCT can be used as a calibrator in procalcitonin or calcitonin immunoassays. Notably, our approach effectively manages small peptides that are prone to degradation by E. coli host proteases, offering a robust solution for various research and application requirements.
我们提出了一种在大肠杆菌 T7 express LysY/Iq 细胞中高效表达和纯化重组人降钙素原(hPCT)的方法,确保了精确的 N 端和 C 端氨基酸序列。我们的方法涉及融合密码子优化的 cDNA 与两个不同的标签序列:eXact 标签和几丁质结合域(CBD)标签。为了纯化蛋白,我们采用两步亲和层析法。首先,我们利用 N 端 Profinity eXact 标签,通过 Profinity eXact-affinity 柱层析,使用固定化突变体枯草杆菌蛋白酶的树脂来纯化蛋白。通过添加 NaF 激活酶,去除 eXact 标签。然后,将含有 C 端 CBD 标签的消化样品直接加载到第二步的几丁质亲和层析中。通过 DTT 催化融合蛋白中内含肽序列的自切割来进行洗脱。结果,目标蛋白以完全无标签的形式选择性地在流穿液中回收,纯度超过 95%。为了确保高纯度并去除潜在的污染物,我们通过硫酸链霉素、Triton X-114 和硫酸铵处理有效地去除大肠杆菌宿主 DNA 和内毒素。获得的极高纯度消除了大多数应用中进一步纯化步骤的需要。这种高度纯化的 hPCT 可作为降钙素原或降钙素免疫分析的校准物。值得注意的是,我们的方法有效地处理了容易被大肠杆菌宿主蛋白酶降解的小肽,为各种研究和应用需求提供了稳健的解决方案。